10-Q: Silexion Therapeutics Corp Reports Q3 2024 Results Following Business Combination

Silexion Therapeutics Corp reports its Q3 2024 results, reflecting the impact of its recent business combination and ongoing development of its cancer treatments.

Summary

• Silexion Therapeutics Corp, a clinical-stage oncology company, released its financial results for the quarter ended September 30, 2024, following a business combination.
• The company's operations are primarily focused on developing treatments for KRAS-driven cancers, with its lead product candidate, SIL-204B, targeting locally advanced pancreatic cancer.
• For the nine-month period ended September 30, 2024, the company reported a net loss of $14.8 million, compared to a net loss of $3.4 million for the same period in 2023.
• Research and development expenses increased to $4.9 million for the nine-month period ended September 30, 2024, up from $2.5 million in the same period of 2023.
• General and administrative expenses also saw a significant increase, reaching $5.7 million for the nine-month period ended September 30, 2024, compared to $0.5 million in the same period of 2023.
• The company's financial position is impacted by the business combination, with a cash balance of $2.0 million as of September 30, 2024.
• Silexion has an accumulated deficit of $41.6 million as of September 30, 2024.
• The company has funded its operations through private offerings, grants, and convertible financing agreements, and is exploring additional funding options.
• The company has received $5.8 million in royalty-bearing grants from the Israeli Innovation Authority (IIA) and is committed to paying royalties on future sales.
• The company has raised $2.5 million through an equity line of credit (ELOC) as of the date of the report.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses, low cash reserves, and a going concern warning. While there are some positives like the business combination and ELOC funding, the overall sentiment is negative due to the company's financial instability and need for additional capital.

Positives

• The company has successfully completed a business combination, becoming a publicly-traded entity.
• Silexion has secured $2.5 million in funding through an equity line of credit (ELOC).
• The company has received $5.8 million in royalty-bearing grants from the Israeli Innovation Authority (IIA).
• The company raised $2 million via a private investment in public entity financing (PIPE).

Negatives

• The company reported a significant net loss of $14.8 million for the nine-month period ended September 30, 2024.
• Operating expenses, including research and development and general and administrative costs, have increased substantially.
• The company has an accumulated deficit of $41.6 million.
• The company's cash balance is relatively low at $2.0 million as of September 30, 2024.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
• The company needs to raise additional capital to fund its operations and development programs.
• The company's reliance on the ELOC for funding could lead to significant dilution of existing shareholders.
• The company's product development is subject to regulatory risks and uncertainties.
• The company's financial performance is subject to market conditions and economic climate.
• The company is subject to royalty payments to the IIA on future sales of products developed using IIA grants.
• The company's share price is below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its product development and clinical trials. The company will need to raise additional capital to fund its operations and expand its business.

Management Comments

• Management is in the process of evaluating various financing alternatives, as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising.
• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the date these financial statements are issued.

Industry Context

The company operates in the biotechnology sector, specifically focusing on oncology and the development of treatments for KRAS-driven cancers. This is a competitive and high-risk area, with significant investment required for research and development, clinical trials, and regulatory approvals. The company's focus on RNA-interference therapeutics is a growing area of interest in the industry.

Comparison to Industry Standards

• Comparing Silexion to other clinical-stage biotech companies, the increase in R&D and G&A expenses is typical as they progress through clinical trials and prepare for potential commercialization.
• The net loss of $14.8 million for the nine-month period is significant, but not uncommon for companies in this stage of development, especially those with high R&D costs and no revenue.
• The cash balance of $2.0 million is low compared to industry standards for companies at this stage, highlighting the need for additional funding.
• The reliance on ELOC financing is a common strategy for early-stage biotech companies, but it can lead to significant dilution for existing shareholders.
• The company's focus on pancreatic cancer and KRAS mutations aligns with current industry trends in targeted cancer therapies.
• Companies like Mirati Therapeutics and Revolution Medicines are also focused on KRAS inhibitors, but they are at a more advanced stage of development and have significantly higher market capitalizations.

Related Party Transactions

• The company has related party transactions with shareholders and directors, including share-based compensation and financial expenses.
• The company issued a promissory note to the sponsor as part of the business combination.

Stakeholder Impact

• Shareholders face significant dilution risk due to the company's reliance on ELOC financing.
• Employees may be impacted by the company's financial instability and potential need for cost-cutting measures.
• Customers (potential patients) may be impacted by delays in product development due to funding constraints.
• Suppliers and creditors may face increased risk due to the company's going concern warning.

Next Steps

• The company will continue to develop its lead product candidate, SIL-204B, and initiate pre-clinical and clinical trials.
• The company will seek marketing approvals for SIL-204B in various territories.
• The company will explore additional funding options, including potential equity financings.
• The company will need to regain compliance with Nasdaq listing requirements by April 28, 2025.

Key Dates

Keywords

Silexion Therapeutics, oncology, KRAS, SIL-204B, pancreatic cancer, siRNA, business combination, financial results, research and development, equity line of credit, ELOC, Israeli Innovation Authority, IIA, promissory note, PIPE financing